NCT00344305 - A Study to Evaluate the Shedding and Safety of Trivalent Influenza Virus Vaccine Live, Intranasal in Infants and Young Children | Biotech Hunter

Enrollment

200

Participants

Timeline

Start Date

May 1, 2006

Primary Completion Date

July 1, 2006

Study Completion Date

December 1, 2006

Conditions

Healthy

Interventions

BIOLOGICAL

Trivalent influenza virus vaccine live, intranasal

A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10\^7 FFU of three influenza virus strains.

Trial Locations (16)

13045

Health Sciences Research Center, Cortland

13760

Regional Clinical Research Inc., Endwell

14901

Health Sciences Research Center, Elmira

15241

Primary Physicians Research , Inc, Pittsburgh

22015

PI-Coor Clinical Research, LLC, Burke

22180

Advanced Pediatrics, Vienna

30062

Pediatric and Adolescent Medicine, PA (PAMPA), Marietta

40004

Kentucky Pediatrics/Adult Research, Bardstown

70006

Benchmark Research, Metairie

72205

Little Rock Allergy & Asthma Clinic, PA, Little Rock

73132

Grand Prairie Pediatrics & Allergy Clinic, Oklahoma City

76904

Benchmark Research, San Angelo

77004

Med-Pro Research Inc., Houston

78130

Central Texas Health Research, New Braunfels

84041

Wee Care Pediatrics, Layton

84604

Utah Valley Pediatrics, Provo